effect
global
control
tuberculosi
tb
increasingli
threaten
converg
multidrugresist
tb
human
immunodefici
viru
hiv
infect
tbhiv
coinfect
exert
tremend
burden
host
immun
system
prompt
clinic
use
immunomodul
enhanc
host
defenc
altern
therapeut
strategi
studi
modifi
clinic
use
synthet
immunomodulatori
pentapeptid
thymopentin
rkdvi
six
arginin
residu
rrrrrr
nand
ctermini
obtain
cation
peptid
rkdvyrrrrrrnh
rrrrrrrkdvynh
respect
arginin
residu
confer
antimycobacteri
activ
peptid
shown
effect
minimum
inhibitori
concentr
mgl
kill
effici
rifampicinsuscept
resist
mycobacterium
smegmati
immunomodulatori
action
peptid
remain
unaffect
shown
abil
stimul
tnfa
product
raw
mous
macrophag
cell
distinct
chang
surfac
morpholog
peptid
treatment
observ
scan
electron
micrograph
confoc
microscopi
dye
leakag
studi
suggest
bacteri
membran
disrupt
modifi
peptid
modifi
peptid
nontox
caus
hemolysi
rat
red
blood
cell
concentr
mgl
moreov
show
synerg
rifampicin
reduc
effect
concentr
rifampicin
prevent
induct
rifampicin
resist
synthet
peptid
may
potenti
applic
immunocompet
immunocompromis
tb
patient
synthet
modif
immunomodul
peptid
thymopentin
confer
antimycobacteri
activ
tuberculosi
tb
caus
bacillu
mycobacterium
tuberculosi
rank
second
lead
caus
death
singl
infecti
agent
human
immunodefici
viru
hiv
although
tb
incid
mortal
rate
fallen
global
rapid
emerg
multidrugresist
mdr
extens
drugresist
xdr
tb
continu
threaten
decad
progress
global
tb
control
mdrtb
estim
incid
case
defin
resist
isoniazid
rifampicin
two
power
firstlin
antitb
drug
xdrtb
strain
account
mdrtb
case
gener
mdrtb
strain
develop
addit
resist
fluoroquinolon
second
line
inject
agent
addit
effort
tackl
mdrtb
complic
tbhiv
coinfect
dramat
reduc
host
immun
increas
individu
suscept
tb
infect
reinfect
includ
drugresist
strain
malabsorpt
antitb
drug
particularli
rifampicin
tbhiv
patient
may
also
predispos
acquisit
drug
resist
progress
toward
earli
diagnosi
develop
shorter
less
toxic
efficaci
treatment
regimen
mdrtb
clearli
prioriti
global
manag
tb
cation
host
defens
peptid
hdp
divers
group
molecul
produc
innat
immun
system
respons
infecti
agent
recent
identifi
potenti
new
class
antiinfect
drug
develop
given
broadspectrum
activ
direct
bactericid
adjunct
immunomodulatori
action
direct
antimicrobi
mechan
hdp
larg
attribut
abil
fold
amphiphil
structur
hydrophob
cation
domain
facilit
physic
interact
neg
charg
bacteri
cell
membran
case
bacteri
cell
penetr
act
intracellular
target
lead
disrupt
membran
integr
cellular
process
respect
aggreg
action
sever
compon
essenti
bacteri
cell
surviv
thu
make
develop
drug
resist
much
less
like
ration
design
directli
antimicrobi
peptid
base
structurefunct
relationship
thu
wide
employ
produc
candid
greater
bactericid
effici
although
often
expens
safeti
may
explain
peptid
use
topic
clinic
trial
adjunct
immunomodulatori
action
hdp
hand
demonstr
anim
model
import
pathogen
clearanc
via
regul
chemotact
activ
dendrit
tcell
induct
proinflammatori
cytokin
lead
enhanc
leukocyt
recruit
site
infect
given
pleiotrop
target
effect
lack
clear
structur
requir
immunomodul
ration
design
immunomodulatori
hdp
rel
challeng
lag
behind
develop
microbi
hdp
nonetheless
immunomodul
recogn
highli
effect
strategi
combat
mdr
infect
especi
immunocompromis
patient
target
action
immun
system
rather
pathogen
present
studi
explor
synthet
modif
clinic
use
immunomodul
thymopentin
confer
cation
mimic
dual
immunomodulatori
antimicrobi
effect
hdp
synthet
pentapeptid
consist
five
amino
acid
arglysaspvaltyr
correspond
amino
acid
sequenc
thymu
hormon
thymopoietin
ref
reproduc
immunomodulatori
activ
thymopoietin
respons
thymocyt
differenti
matur
besid
induc
phenotyp
differenti
precursor
cell
vitro
regul
express
cell
surfac
marker
human
thymocyt
abil
boost
tcell
mediat
immun
respons
use
clinic
treatment
primari
immunodefici
acquir
immunodefici
syndrom
aid
sever
acut
respiratori
syndrom
sar
rheumatoid
arthriti
atop
dermat
conjug
six
arginin
amino
acid
residu
either
ctermini
obtain
cation
peptid
candid
evalu
antimycobacteri
activ
minimum
inhibitori
concentr
mic
kill
effici
timekil
measur
drugsuscept
drugeresist
mycobacterium
smegmati
synergist
interact
also
determin
cotreat
smegmati
rifampicin
peptid
via
chequerboard
assay
preliminari
evalu
antimicrobi
mechan
peptid
carri
use
confoc
scan
electron
microscopi
via
abil
induc
leakag
encapsul
fluorophor
larg
unilamellar
vesicl
compos
neg
charg
phospholipid
lastli
confirm
retent
immunomodulatori
activ
modifi
peptid
perform
elisa
assay
induct
tumor
necrosi
factor
tnf
raw
mous
macrophag
cell
peptid
candid
rkdvi
rrrrrr
rkdvyrrrrrrnh
custom
synthes
gl
biochem
shanghai
china
molecular
weight
confirm
matrixassist
laser
desorptionion
timeofflight
mass
spectroscopi
malditof
ms
model
appli
biosystem
usa
use
acid
chca
matrix
smegmati
atcc
purchas
atcc
usa
nutrient
broth
acumedia
bacteriolog
agar
acumedia
purchas
neogen
corpor
michigan
usa
ethanol
analyt
grade
glutaraldehyd
synthet
grade
h
fitclabel
dextran
kda
dmso
calcein
purchas
sigmaealdrich
singapor
dulbecco
modifi
eagl
medium
dmem
lipopolysaccharid
lp
escherichia
coli
strain
purchas
sigmaealdrich
st
loui
mo
usa
phosphatebuff
salin
pb
ph
concentr
purchas
base
singapor
use
dilut
desir
concentr
phospholipid
racglycerol
pg
dope
obtain
dri
powder
avanti
polar
lipid
inc
alabast
al
usa
rat
red
blood
cell
rrbc
use
studi
obtain
anim
handl
unit
biomed
research
center
ahu
brc
singapor
synthesi
peptid
carri
fmocsolid
phase
protocol
gl
biochem
shanghai
china
malditof
ms
carri
confirm
characterist
peptid
molecular
weight
peptid
measur
spot
equal
volum
peptid
solut
mgml
deioniz
water
chca
solut
satur
acetonitrilewat
mixtur
volum
ratio
onto
maldi
groundsteel
target
plate
shown
tabl
close
agreement
measur
theoret
molecular
weight
peptid
revers
phase
rp
hplc
use
manufactur
confirm
puriti
peptid
mic
peptid
determin
broth
microdilut
method
describ
previous
briefli
serial
dilut
peptid
mgl
prepar
ad
equal
volum
bacteri
solut
ml
contain
approxim
cfuml
well
plate
plate
incub
c
shake
speed
rpm
read
h
mic
defin
lowest
peptid
concentr
microbi
growth
observ
visual
spectrophotometr
via
read
optic
densiti
od
nm
use
micropl
reader
tecan
switzerland
growth
media
contain
microbi
cell
use
neg
control
mic
test
carri
replic
repeat
time
vitro
kill
kinet
peptid
perform
accord
previous
report
method
slight
modif
flask
contain
ml
nutrient
broth
peptid
concentr
correspond
mic
inocul
smegmati
densiti
approxim
cfu
ml
incub
c
h
shake
rpm
determin
synergist
interact
peptid
rifampicin
similar
studi
perform
rifampicin
alon
combin
mic
aliquot
remov
time
h
postinocul
serial
dilut
nutrient
broth
determin
viabl
count
dilut
sampl
ml
plate
triplic
onto
agar
plate
total
bacteri
count
determin
incub
c
h
kill
effici
studi
perform
similarli
sampl
taken
h
result
express
mean
log
cfu
ml
ae
standard
deviat
dyefil
larg
unilamellar
vesicl
luv
prepar
use
extrus
method
previous
establish
calcein
dye
dissolv
buffer
contain
mm
na
hpo
h
ph
achiev
concentr
mm
prepar
pepg
luv
ml
pe
ml
pg
dissolv
mgml
chcl
combin
make
ml
chcl
clean
round
bottom
flask
chcl
solvent
remov
rotari
evapor
obtain
thin
lipid
film
hydrat
ml
calcein
solut
mixtur
left
stir
rotari
evapor
atmospher
pressur
h
subject
ten
freeze
thaw
cycl
use
dri
iceaceton
freez
warm
water
thaw
suspens
extrud
twenti
time
polycarbon
membran
nm
pore
diamet
sephadex
column
use
remov
free
dye
use
buffer
compos
mm
na
hpo
mm
nacl
eluent
dyefil
luv
dilut
time
eluent
buffer
achiev
final
lipid
concentr
approxim
mm
use
evalu
abil
peptid
ruptur
dyefil
luv
ml
dilut
vesicl
mix
ml
peptid
solut
variou
concentr
mgl
plate
shaken
h
calcein
fluoresc
emiss
intens
ex
nm
em
nm
measur
micropl
reader
tecan
switzerland
calcein
fluoresc
without
peptid
treatment
use
baselin
fluoresc
emiss
addit
ml
tritonx
dmso
x
taken
leakag
percentag
leakag
calcul
leakag
leakag
shown
treatment
pure
dmso
ml
smegmati
suspens
seed
wellcov
slip
chamber
equal
volum
pb
solut
contain
mgl
fitcdextran
kda
mgl
ad
mixtur
incub
predetermin
period
time
min
min
min
c
constant
shake
rpm
wash
three
time
pb
remov
free
fitcdextran
imag
acquir
use
zeiss
meta
confoc
microscop
equip
oil
plan
apochrom
len
bacteri
cell
prepar
mic
measur
treat
peptid
mgl
shorter
incub
time
h
treatment
bacteria
centrifug
rpm
min
wash
time
pb
sampl
fixat
perform
glutaraldehyd
min
follow
wash
pb
final
deioniz
water
sampl
dehydr
carri
use
seri
grade
ethanol
solut
follow
dri
two
day
dri
sampl
mount
carbon
tape
sputter
platinum
coat
analyz
field
emiss
scan
electron
microscop
jeol
japan
assess
safeti
peptid
mammalian
cell
hemolyt
activ
test
use
freshli
drawn
rat
red
blood
cell
rrbc
obtain
anim
hold
unit
ahu
biomed
research
center
brc
singapor
rrbc
dilut
time
pb
give
blood
content
report
previous
serial
dilut
peptid
prepar
use
pb
concentr
rang
mgl
equal
volum
ml
peptid
solut
blood
suspens
mix
mixtur
incub
c
h
facilit
interact
rrbc
peptid
subsequ
mixtur
centrifug
g
min
ml
supernat
transfer
micropl
hemoglobin
releas
determin
spectrophotometr
measur
absorb
sampl
nm
via
micropl
reader
tecan
switzerland
untreat
rrbc
serv
neg
control
rrbc
treat
tritonx
serv
posit
control
test
carri
replic
reproduc
twice
degre
hemolysi
calcul
use
follow
formula
hemolysi
chequerboard
assay
perform
determin
effect
combin
peptid
rifampicin
treatment
smegmati
set
mixtur
ml
prepar
vari
rifampicin
concentr
accord
tabl
drug
resist
induc
smegmati
repeat
treatment
passag
establish
via
mic
measur
abovement
treatment
bacteri
cell
expos
submic
concentr
mic
particular
passag
regrown
log
phase
reus
follow
passag
mic
measur
chang
mic
depict
normal
mic
passag
n
first
passag
abil
peptid
well
modul
immun
respons
evalu
measur
product
proinflammatori
cytokin
tumor
necrosi
factor
tnfa
raw
mous
macrophag
cell
cell
kindli
provid
dr
ho
han
kiat
depart
pharmaci
nation
univers
singapor
singapor
cultur
dmem
supplement
fb
uml
penicillin
g
mgml
streptomycin
humidifi
atmospher
c
contain
co
cell
seed
densiti
cell
ml
plate
h
treat
final
concentr
mm
serumfre
medium
h
media
collect
centrifug
g
min
spin
cell
cellfre
supernat
use
conduct
tnfa
elisa
assay
per
manufactur
instruct
lipopolysaccharid
lp
bacteri
cell
wall
compon
known
stimul
tnfa
product
raw
cell
use
concentr
ngml
posit
control
absorb
read
taken
nm
wavelength
correct
nm
use
infinit
pro
spectrophotomet
tecan
switzerland
amount
tnfa
releas
upon
peptid
treatment
quantifi
use
regress
equat
gener
standard
curv
experi
perform
triplic
report
mean
ae
sem
data
analyz
use
oneway
anova
follow
dunnett
posthoc
analysi
spss
chicago
il
differ
valu
treatment
consid
statist
signific
p
report
antimicrobi
activ
peptid
could
enhanc
replac
acid
residu
basic
one
increas
net
posit
charg
henc
order
amplifi
antimicrobi
abil
reason
increas
cation
includ
posit
charg
amino
acid
peptid
sequenc
furthermor
peptid
consist
six
arginin
enter
cell
far
effect
peptid
equal
length
contain
lysin
ornithin
histidin
howev
peptid
fewer
six
amino
acid
ineffect
therefor
engin
short
peptid
compos
six
arginin
residu
alon
short
peptid
capabl
induc
pronounc
growth
inhibit
rifampicin
rif
suscept
rifresist
smegmati
mic
valu
mgl
tabl
fig
rifresist
smegmati
develop
multipl
treatment
drugsuscept
smegmati
rifampicin
submic
concentr
mic
mic
concentr
rifampicin
increas
mgl
mgl
fig
expect
could
inhibit
bacteri
growthup
highest
concentr
use
mgl
howev
upon
addit
six
arginin
residu
either
cor
nterminu
modifi
peptid
becam
activ
smegmati
mic
similar
addit
kill
effici
greater
achiev
respect
mic
suggest
bactericid
effect
peptid
rifsuscept
rifresist
smegmati
fig
effect
valid
use
vitro
timekil
assay
analyz
fraction
cell
surviv
upon
peptid
treatment
none
mic
mic
mic
h
fig
show
bactericid
defin
log
decreas
initi
inoculum
h
mic
mic
result
support
success
confer
antimicrobi
activ
immunomodul
via
increas
cation
charg
densiti
peptid
luv
employ
contain
fluoresc
calcein
dye
mimic
loss
cellular
content
upon
membran
ruptur
bacteria
concentrationand
timedepend
increas
dye
leakag
observ
peptid
treatment
indic
peptid
highli
effici
disrupt
integr
simul
bacteri
membran
fig
verifi
potenti
damag
bacteri
cell
membran
smegmati
expos
mgl
min
min
min
presenc
fluoresc
fitclabel
kda
dextran
molecul
mgl
observ
confoc
microscop
evid
dextran
uptak
fig
contrast
control
group
incub
pb
alon
fitcdextran
gain
entri
smegmati
readili
min
incub
give
fluoresc
signal
becom
intens
longer
incub
entri
fitc
dye
indic
microbi
cell
membran
damag
treatment
observ
support
sem
visual
cell
lysi
demonstr
chang
surfac
morpholog
smegmati
rodshap
structur
smooth
surfac
flaccid
shrunken
structur
distort
surfac
h
incub
mgl
fig
influenc
structur
integr
bacteri
membran
interest
find
rel
specif
peptid
mammalian
cell
evalu
hemolysi
test
measur
abil
peptid
lyse
rat
red
blood
cell
vitro
fig
show
peptid
display
minim
hemolyt
effect
even
concentr
high
mgl
concentr
time
mic
peptid
mgl
tabl
confirm
peptid
high
select
toward
bacteri
cell
desir
expand
therapeut
window
clinic
applic
cation
peptid
consid
promis
antibiot
candid
base
fact
peptid
less
like
develop
drug
resist
broad
spectrum
activ
howev
spite
advantag
clinic
usag
limit
due
drawback
poor
potenc
specif
vivo
stabil
overcom
shortcom
translat
laboratori
discoveri
clinic
synergist
effect
peptid
tradit
antibiot
appli
synergi
reduc
dose
drug
combin
prevent
drug
resist
result
greater
antibacteri
effect
sum
effect
due
singl
agent
rifampicin
report
act
synergist
administ
conjunct
antimicrobi
peptid
possibl
consequ
peptidemedi
membran
disrupt
turn
enhanc
uptak
drug
determin
interact
rifampicin
synergi
studi
perform
use
chequerboard
assay
fig
show
minimum
effect
concentr
agent
use
combin
achiev
synergi
inhibit
growth
smegmati
mic
mic
rifampicin
calcul
fici
valu
timekil
studi
perform
valid
synergist
effect
fig
show
rifampicin
use
alon
singl
agent
mic
could
inhibit
growth
smegmati
combin
success
inhibit
bacteri
growth
synergi
defin
log
decreas
cfuml
drug
combin
compar
activ
constitu
synergist
activ
observ
combin
group
h
h
confirm
reduct
viabl
coloni
count
log
compar
singl
activ
constitu
induct
drug
resist
use
evalu
possibl
peptid
induc
drug
resist
mycobacteria
multipl
treatment
low
submic
concentr
fig
show
repeat
treatment
rifampicin
mic
concentr
smegmati
becam
resist
rifampicin
earli
passag
mic
smegmati
rose
dramat
approxim
fold
passag
contrast
remain
equal
activ
passag
demonstr
mainten
mic
valu
throughout
result
support
hypothesi
differ
mechan
antimycobacteri
action
may
exploit
combin
therapi
evad
drug
resist
singl
agent
shown
induc
cytokin
tnfa
product
unstimul
macrophag
part
immunomodulatori
function
henc
address
retent
biolog
activ
modifi
peptid
elisa
assay
perform
measur
compar
level
tnfa
releas
peptid
treatment
raw
macrophagelik
cell
amount
tnfa
releas
differ
peptid
although
level
compar
releas
respons
lp
stimul
macrophag
p
fig
level
significantli
higher
peptid
absent
cell
media
p
result
show
despit
structur
modif
biolog
activ
remain
unperturb
notabl
report
tnfa
essenti
control
tb
infect
inflammatori
bowel
diseas
ibd
patient
also
latent
infect
tuberculosi
approach
counteract
increas
serum
level
tnfa
tnfaneutr
agent
infliximab
led
tb
reactiv
abil
induc
tnfa
fig
tnfa
product
raw
macrophag
cell
treat
peptid
mm
repres
p
ns
repres
signific
abil
induc
tnfa
product
maintain
modifi
peptid
product
specif
modifi
peptid
may
thu
complement
antimycobacteri
action
effect
therapeut
manag
tb
present
studi
demonstr
cation
charg
bestow
repeat
arginin
residu
confer
antimycobacteri
activ
drugsuscept
drugresist
strain
clinic
use
immunomodul
mechanist
investig
use
dye
leakag
assay
microscopi
reveal
modifi
peptid
function
via
membranolyt
action
may
account
synergist
action
firstlin
antitb
drug
rifampicin
despit
structur
modif
hemolysi
henc
toxic
kept
low
biolog
activ
well
retain
indic
abil
stimul
tnfa
product
macrophag
result
demonstr
synthet
peptid
possess
dual
antimycobacteri
immunodulatori
effect
may
potenti
evad
drug
resist
immunocompet
immunocompromis
tb
patient
